Sieger Stephanie, Jiang Shiming, Schönsiegel Frank, Eskerski Helmut, Kübler Wolfgang, Altmann Annette, Haberkorn Uwe
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre, Heidelberg, Germany.
Eur J Nucl Med Mol Imaging. 2003 May;30(5):748-56. doi: 10.1007/s00259-002-1099-4. Epub 2003 Jan 23.
Targeted transfer of a functionally active sodium iodide symporter (NIS) into tumour cells may be used for radioiodine therapy of cancer. Therefore, we investigated radioiodine uptake in a hepatoma cell line in vitro and in vivo after transfer of the sodium iodide symporter ( hNIS) gene under the control of a tumour-specific regulatory element, the promoter of the glucose transporter 1 gene (GTI-1.3). Employing a self-inactivating bicistronic retroviral vector for the transfer of the hNIS and the hygromycin resistance genes, rat Morris hepatoma (MH3924A) cells were infected with retroviral particles and hNIS-expressing cell lines were generated by hygromycin selection. (125)I(-) uptake and efflux were determined in genetically modified and wild type hepatoma cells. In addition, the iodide distribution in rats bearing wild type and genetically modified hepatomas was monitored. hNIS-expressing MH3924A cell lines accumulated up to 30 times more iodide than wild type hepatoma cells, with a maximal iodide uptake after 30 min incubation time. Competition experiments in the presence of sodium perchlorate revealed a decrease in the iodide uptake (80-84% decrease). Moreover, ouabain led to a loss of accumulated I(-) (81% decrease) whereas 4,4'-diisothiocyano-2,2'-disulphonic acid stilbene (DIDS) increased the I(-) uptake into cells (87% increase). However, a rapid efflux of the radioactivity (70%) was observed 20 min after (125)I(-)-containing medium had been replaced by non-radioactive medium. Lithium had no significant effect on iodide efflux. In rats, the hNIS-expressing tumours accumulated 22 times more iodide than the contralateral wild type tumour. In accordance with the in vitro data, we also observed a rapid efflux of the radioactivity out of the tumour in vivo. Dosimetric calculations resulted in an absorbed dose of 85 mGy in the wild type tumour and 830 mGy in the hNIS-expressing tumour after administration of 18.5 MBq (131)I. In conclusion, transduction of the hNIS gene under the control of the GLUT1 promoter element induces iodide transport in Morris hepatoma cells in vitro and in vivo. However, for therapeutic application additional conditions need to be defined which inhibit the iodide efflux out of the tumour cells.
将功能活性钠碘同向转运体(NIS)靶向转移至肿瘤细胞可用于癌症的放射性碘治疗。因此,我们研究了在肿瘤特异性调控元件——葡萄糖转运体1基因(GTI-1.3)启动子的控制下,转移钠碘同向转运体(hNIS)基因后,肝癌细胞系在体外和体内对放射性碘的摄取情况。利用一种自失活双顺反子逆转录病毒载体来转移hNIS和潮霉素抗性基因,用逆转录病毒颗粒感染大鼠莫里斯肝癌(MH3924A)细胞,并通过潮霉素筛选产生表达hNIS的细胞系。测定转基因肝癌细胞和野生型肝癌细胞中(125)I⁻的摄取和流出情况。此外,监测了携带野生型和转基因肝癌的大鼠体内碘的分布情况。表达hNIS的MH3924A细胞系积累的碘比野生型肝癌细胞多30倍,孵育30分钟后碘摄取量达到最大。在高氯酸钠存在下的竞争实验显示碘摄取量减少(减少80 - 84%)。此外,哇巴因导致积累的I⁻丢失(减少81%),而4,4'-二异硫氰酸-2,2'-二磺酸芪(DIDS)增加了细胞对I⁻的摄取(增加87%)。然而,在用含(125)I⁻的培养基替换为无放射性培养基后第20分钟,观察到放射性迅速流出(70%)。锂对碘流出没有显著影响。在大鼠中,表达hNIS的肿瘤积累的碘比同侧野生型肿瘤多22倍。与体外数据一致,我们在体内也观察到放射性从肿瘤中迅速流出。剂量学计算结果显示,给予18.5 MBq(131)I后,野生型肿瘤的吸收剂量为85 mGy,表达hNIS的肿瘤为830 mGy。总之,在GLUT1启动子元件控制下转导hNIS基因可在体外和体内诱导莫里斯肝癌细胞中的碘转运。然而,对于治疗应用,需要确定抑制碘从肿瘤细胞中流出的其他条件。